Vaxcyte PCVX 深 滬
已收盤 05-08 16:00:00 美东时间
53.01
+1.530
+2.97%
華盛通- 最 高53.39
- 今 開50.82
- 成交量 191.72万股
- 最 低 50.82
- 昨 收 51.48
- 總市值 76.54亿
- 52周最高 65.00
- 市盈率 靜 --
- 換手率 1.33%
- 52周最低 29.08
- 委 比 95.88%
- 總股本 1.44亿
- 歷史最高 121.055
- 量 比 0.86
- 振 幅 4.99%
- 歷史最低 15.51
- 每 手 1
- 風險率 10.34%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Vaxcyte shares are trading lower after the company reported worse-than-expected Q1 EPS results.
Vaxcyte shares are trading lower after the company reported worse-than-expected...
05-08 03:05
财报速睇 | Vaxcyte 2026财年Q1营收0.00亿美元，同比增长0.0%；归母净利润亏损3.21亿美元，同比亏损扩大127.8%
华盛资讯5月7日讯，Vaxcyte公布2026财年Q1业绩，公司Q1营收0.00亿美元，同比增长0.0%，归母净利润亏损3.21亿美元，同比亏损扩大127.8%。
05-07 09:38
财报速睇 | Vaxcyte 2026财年Q1营收0.00亿美元，同比增长0.0%；归母净利润亏损3.21亿美元，同比亏损扩大127.7%
华盛资讯5月7日讯，Vaxcyte公布2026财年Q1业绩，公司Q1营收0.00亿美元，同比增长0.0%，归母净利润亏损3.21亿美元，同比亏损扩大127.7%。
05-07 08:32
Earnings Scheduled For May 6, 2026
Companies Reporting Before The Bell • Deluxe (NYSE:DLX) is expected to report q...
05-07 05:03
Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update
Vaxcyte announced the completion of enrollment for their OPUS-1, OPUS-2, and OPUS-3 Phase 3 trials for VAX-31, with safety and immunogenicity data expected in late 2026 and early 2027. The VAX-31 infant Phase 2 study has also completed enrollment, with results anticipated by mid-2027. VAX-A1, a vaccine for Group A Strep, is set to begin Phase 1 trials mid-2026. The company reported $2.7 billion in cash as of March 2026, following a $601.8 million...
05-06 20:05
Vera Therapeutics appoints Jane Wright-Mitchell chief legal officer
Vera Therapeutics appoints Jane Wright-Mitchell chief legal officer Vera Therapeutics appointed Jane Wright-Mitchell as Chief Legal Officer, effective immediately. Wright-Mitchell previously served as a fractional general counsel supporting public and private life sciences companies. Her prior roles
03-25 19:30
Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer
Vera Therapeutics appoints Jane Wright-Mitchell, Pharm.D., J.D., as Chief Legal Officer, leveraging her over 25 years of experience in legal and compliance matters within the life sciences industry. Her expertise will support Vera’s upcoming commercial launch of atacicept, a dual BAFF/APRIL inhibitor for IgA nephropathy, and strengthen the company’s legal framework. Wright-Mitchell previously served as General Counsel at Vaxcyte, Inc. and brings ...
03-25 11:30
Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
Vaxcyte Inc. announced positive results from a Phase 1/2 study of VAX-31, a 31-valent pneumococcal conjugate vaccine candidate, in adults aged 50 and older. The study demonstrated robust opsonophagocytic activity and immunoglobulin G immune responses across all 31 serotypes, with a safety profile similar to PCV20. VAX-31 achieved non-inferiority criteria for 20 serotypes common with PCV20 and superiority for 11 unique serotypes. The high-dose VAX...
03-18 23:34
美股大行评级 | 最高300美元！大摩、小摩、花旗纷纷上调英伟达目标价；赛富时、C3.ai、Snowflake、Trade Desk等遭数十家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持NovoCure"买入"评级，目标价从47美元升至49美元；Citizens：维持Ironwood医药"跑赢大市"评级，目标价从8美元升至10美元
02-27 11:07
